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Abstract
Naxos disease, first described by Dr. Nikos Protonotarios and colleagues on the island of Naxos, Greece, is a special
form of arrhythmogenic right ventricular dysplasia (ARVD). It is an inherited condition with a recessive form of
transmission and a familial penetrance of 90%. It is associated with thickening of the skin of the hands and sole,
and a propensity to woolly hair. The cardiac anomalies characterized by ventricular arrhythmias with ventricular
extrasystoles and tachycardia and histologic features of the myocardium are consistent with ARVD, but in a more
severe form of dysplasia with major dilatation of the right ventricle. The identification of the responsible first gene
on chromosome 17, and its product plakoglobin as the responsible protein for Naxos disease proved to be a
milestone in the study of ARVD, which opened a new field of research. Thanks to those with the determination to
discover Naxos disease, there is and will be more clarity in understanding the mechanisms of juvenile sudden
death in the young who have an apparently otherwise normal heart.
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Background
Arrhythmogenic right ventricular dysplasia (ARVD) was
first recognized in 1977 during antiarrhythmic surgery
in Pitié Salpêtrière Hospital, Paris, France [1]. The dys-
plasia predominantly involved the original “triangle of
dysplasia” (Fig. 1). The diagnosis of ARVD was patho-
logically based on previous findings of myocardium em-
bedded in or bordered by fatty tissue and/or fibrosis
(Fig. 2) [1–4]. Biventricular involvement (Fig. 3) is very
frequently observed at later stages, leading to congestive
heart failure and death [5–10]. Naxos disease is a special
form of ARVD, which was first described by Dr. Nikos
Protonotarios and colleagues on the island of Naxos,
Greece [11] and then in other regions [12–21]. It is an
inherited condition with a recessive form of transmission
and a familial penetrance of 90% [11, 22–27]. It is asso-
ciated with thickening of the skin of the hands and sole,
and a propensity to woolly hair. The cardiac anomalies
characterized by ventricular arrhythmias with ventricular
extrasystoles and tachycardia and histologic features of
the myocardium are consistent with ARVD, but in a
more severe form of dysplasia with major dilatation of
the right ventricle [23, 25, 26, 28–30]. The identification
of the responsible first gene on chromosome 17, and its
product plakoglobin as the responsible protein for Naxos
disease proved to be a milestone in the study of ARVD,
which opened a new field of research [28, 31]. In this re-
view, we provide an impressive historical overview of
events and developments that lead to the appearance of
the Naxos disease concept in the context of ARVD. The
review provides a first-hand account and bears a great
deal of personal touch in description of the important
historical events.
The Hellenic era (400 BC)
The most famous of the Greek myths, even though they
seem to be deeply rooted in the imagination and spring-
ing from the world of legends rather than historical
truth, have nevertheless always had the reputation of
expressing an aspect of reality. One can ask oneself
whether the myth about a famous Marathon runner,
who brought the Athenian general Miltiades the victory
over the Persians conducted by the king Darius the
Great, was the first recorded case of sudden death from
ARVD. This story tells of a fit and healthy young man
proclaiming, “Victory!” upon his completion of a pro-
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collapsed and died suddenly. A closer reading of the
texts, which provide accounts of this runner, however,
reveal differing views of what actually occurred. Heratus
recounts a unique and remarkable version of this story.
He describes the messenger Philippides striding to re-
quest help from the Spartans, the traditional enemies of
the Athenians’, before the dreadful Battle of Marathon.
Aristophanes, the first Greek comic poet, transforms the
name Philippides into Pheidippides. This name then ap-
pears to have the etymology of a man belonging to “a
family known for taking care of horses.” Being the best
runner of his family, he would have preferred to run the
exhausting distance himself in order to spare his steed.
An important step towards learning the genetic as-
pects of ARVD began with the study of an uncommon
illness, which may well have affected lives long ago. This
illustrates William Harvey’s well-known saying that the
study of uncommon illnesses often allows us to better
understand the mechanisms of common diseases. This is
indeed what happened, when Naxos disease made its ap-
pearance on the medical stage.
The following brief reminder of what the name
“Naxos” can evoke in the memories of those, who have
been privileged to visit the Greek world, seems an ap-
propriate introduction to describe how Naxos disease
was identified.
Island of Naxos
Situated to the North East of a group of islands called
the Cyclades, Naxos is the largest one of these islands
(Fig. 4). Mountainous and bisected by deep valleys,
groups of inhabitants live on the valley floors quite iso-
lated from one another, though less than they were in
former times. According to the legend, Naxos was the
Isle of Dionysos, the God of vines and wine who was
born from the thigh of his father Jupiter. The story
blends the power of the gods with their hidden weak-
nesses. According to another Greek legend, the Island of
Naxos was where Ariadne was abandoned by Theseus
on his way back to Athens. Theseus had been able to
slay the Minotaur thanks to Ariadne who had given him
the thread that led him out of the labyrinth. The story,
however, says that Theseus boarded his ship and sailed
away while Ariadne slept. This melancholic tale has a
trace in the French literature, in the beautiful words of
Racine’s tragedy “Phedre”:
“Ariadne, my sister, of what unrequited love did you
die on the coast where you were abandoned?”
Music-lovers may recall the symphonic poem by Al-
bert Roussel or the masterpiece opera by Richard Strauss
“Ariadne on Naxos”.
Fig. 1 The heart of a 50-year-old female ARVD patient during
surgery. The most prominent areas of dysplasia are illustrated on
the drawing. Triangle of dysplasia: the most frequent sites of
dysplasia: (1) the anterior infundibulum, (2) the right ventricular
apex and (3) the inferior or diaphragmatic aspect of the right
ventricle (RV). These constitute the original “triangle of dysplasia”.
LV - left ventricle, RA - right atrium. (With permission from Marcus FI &
Fontaine GH, et al. [7])
Fig. 2 a, Surviving strands of cardiomyocytes bordered by or
embedded in extensive adipose tissue (magnification× 100). b, Most of
the myocardial fibers are dissociated by fat and minor fibrosis. (Spongy
structure) The pictures were obtained from GF´s personal collection
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Fig. 4 Island of Naxos is situated to the North East of a group of islands called the Cyclades. The original map was obtained from Google Maps
Fig. 3 Representative biventricular dysplasia in ARVD. The same disease process, replacement of myocardium by fat and fibrosis, is observed in
this patient on the right as well as external part of the left ventricle (a). Inside fat, there are surviving cardiomyocytes (b) and zones of fibrosis (c).
(Reprinted with permission from Guy Fontaine, et al. [10])
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Athens European cardiology congress (1968)
Quite apart from its cultural resonance, Greece has a
very special significance, since it was the country where
one of the authors (GF) first achieved international rec-
ognition for some of his first work on cardiac pacing. GF
had submitted two abstracts to the Athens European
Cardiology Congress in 1968. These documents con-
cerned the value of threshold measurements in cardiac
pacing, and both were accepted for oral presentation.
Naxos disease
Indeed it was on this island, rich in reminders of mytho-
logical happenings, that a modern-day rural doctor, gen-
eral practitioner, at that time, made a keen observation.
The doctor noted that some of his patients possessed
two pathologies apparently independent of one another,
and yet unquestionably linked. On the one hand, an
ectodermic dysplasia manifested itself in the form of pal-
moplantar keratosis, i.e. a thickening of the skin of the
hands and sole, and a propensity to woolly hair (Fig. 5)
[11]. On the other hand, cardiac anomalies were present
(Figs. 6, 7 and 8). These were characterized by ventricu-
lar rhythm disorders with ventricular extrasystoles and
tachycardia (Fig. 9). There were also structural abnor-
malities with large areas of fibro-fatty tissue bordering
surviving fibers of myocardium (Fig. 10).
After having collected various cases, the cardiologist
realized that the illness seemed to run in families. He
wanted to find the origin of these two such disparate
sets of symptoms. The first, the keratosis, was known to
Greek dermatologists. It was thought that it could be
related to Meleda disease, [32, 33] present in this part of
the world and throughout the Mediterranean area,
reaching as far as the Dalmatian coast. The cardiac
anomaly was more mysterious.
Preliminarily, Dr. Nikos Protonotarios sought the as-
sistance of Greek academics in Athens. The first ques-
tion to be answered was whether a clinical entity of this
sort of disease had ever been previously described. Hav-
ing learned that it had not, Dr. Adalena Tsatsopoulou
decided to consult the most comprehensive library to
which they could gain access. The Elsevier Library in
Amsterdam offered learned works, journals and books
over which the doctors poured for more than a month
to search the whole of Index Medicus back to 1895.
They finally lit upon an article which triggered their
interest. It had been written by a Frenchman in English
and was published in a Japanese journal distributed by a
German publisher [34]. The article had been written by
one of us (GF) after the occasion of the third Mikamo
lecture that GF had given in Osaka in 1983. The presen-
tation in Osaka was based on the beginnings of surgery
as a cure for ventricular tachycardia (VT), a rather ag-
gressive procedure, which could be replaced by some-
thing simpler. The piece in the journal had seemed
incumbent upon GF to write something which would
draw together the strands of knowledge about ARVD at
that time. It was this article, describing a new pathology
of the “right ventricle,” that had caught the attention of
Dr. Nikos Protonotarios and colleagues. The doctors had
a reason to believe that they had identified a new clinical
entity whose closest expression in cardiological terms
was that of ARVD, common to a number of patients
within whom Dr. Nikos Protonotarios observed that both
the ectodermic dysplasia and cardiac anomalies were the
intractable arrhythmias and cardiac abnormalities in terms
of major dilatation of the right ventricle. A groundbreak-
ing paper describing these cases was written by Dr. Nikos
Protonotarios and Dr. Adalena Tsatsopoulou and several
of their colleagues. In 1986, the British Heart Journal
Fig. 5 Cutaneous phenotype of Naxos disease: woolly hair (a), palmar (b) and plantar (c) keratosis. Protonotarios N, Tsatsopoulou A. Naxos
disease: cardiocutaneous syndrome due to cell adhesion defect. Original materials from an open access article [23]
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published this excellent paper [11]. A unique note in the
chart of each patient, who was mentioned in the docu-
ment, was that they had descended from families on the
Greek island of Naxos [11].
Two Naxians in Paris
Our team in Paris had become particularly skilled in
the use of ablative methods by 1987 when, for that
reason, we were chosen to receive a Naxian patient.
When the 34-year-old patient arrived in the Jean Ros-
tand Hospital, Sèvres, France, the main consideration
was his most obvious symptom, that of repeated and
intractable VT. A thorough cardiac examination re-
vealed a left ventricle with normal function and all
other aspects to be normal. The patient was treated
by means of fulguration in the right ventricle after
undergoing the usual evaluation procedures in cases
of this disorder. Antiarrhythmic therapy, based on
programmed stimulation, was also found to be effect-
ive. This treatment greatly reduced the number of at-
tacks, which led to the declaration of a satisfactory
clinical condition within a few weeks.
A few years later, the second Naxian case was sent.
This time, the patient had a healthy condition which
seemed to be much more worrying. His left ventricle
was affected by major segmentary anomalies of con-
traction. Angiography results showed a left ventricular
ejection fraction of 35%. This patient was also suc-
cessfully treated.
Looking back over our case notes, we found that
we could not file the Naxian cases along with our
local dysplasia cases. The first Greek patient pre-
sented with palmoplantar keratosis, this did not exist
in any of our other cases. The second Greek patient
presented with evidence of changes to the left ven-
tricle. This led us to suspect a much deeper myocar-
dial pathology that could not really be classified as a
typical right ventricular dysplasia.
Toward genetics
Some months after treating the second patient, as GF
prepared to send his case notes back to Naxos, Greece,
GF was struck by the idea that dysplasia could be con-
sidered as a “morbid association” of Meleda’s disease.
This thought made the second case even more curious,
as his angiographies had shown that he was unquestion-
ably suffering from a major left ventricular lesion. These
events unfolded at a time when the left ventricle’s in-
volvement in dysplasia had not been entirely elucidated.
Thoughts about this “morbid association” engendered
a pressing desire. The histories of the Greek families
whose members were affected by these two differing
pathologies would need to be explored in greater depth.
In order to do this, we would have to contact Dr. Nikos
Protonotarios. A letter sent to the Athens’ address men-
tioned in the British Heart Journal [11] article was
returned, “unknown at this address”. Fortunately, GF
Fig. 7 A 6-year-old male child with Carvajal syndrome (variant of
Naxos disease): Chest X-ray posteroanterior view showing left-sided
cardiomegaly. Original materials from an open access article: [57]
Fig. 6 The cardiac abnormality of Naxos disease was not clinically
manifest until the patient was ≈15 years of age, and onset was
usually with palpitations or syncope. Two-dimensional echocardiogram
of the heart showing typical features of ARVD: severe right ventricular
(RV) dilatation and multiple saccular aneurysmal segments (arrows).
There is also right atrial (RA) dilatation. In contrast, the left ventricle (LV)
and left atrium (LA) are normal. Accompanying ECG shows abnormal
T-wave inversion in leads V1 through V4, consistent with abnormal
repolarization affecting the RV. Epsilon waves are also observed.
Original materials from an open access article [23]
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had a very grateful patient living in Athens at the time.
Thanks to his assistance, GF was able to track down Dr.
Nikos Protonotarios in less than 48 h. Dr. Nikos Proto-
notarios had returned to his birthplace and established a
private clinic. He was a prestigious and practicing cardi-
ologist on the island of Naxos, Greece.
Contacting Dr. Nikos Protonotarios was immediately
gratifying. He was willing to collaborate with our team
in their efforts to study this strange affliction. We
expressed our conviction, to which importance should
be attached, was in observing the clinical condition in
the Hellenic families, i.e. the association of probable
ARVD with visible palmoplantar keratosis. Preliminary
studies of the patients’ pedigrees suggested a direction
for additional observations. It seemed possible that the
condition was transmitted to the subjects inhabiting the
island through a recessive gene as stressed in the original
publication in the British Heart Journal [11].
The situation on Naxos seemed to echo the genetic
findings of a study in England [35]. Incidentally, that
study was made when myocardial pathologies were just
beginning to be identified and were still referred to as
cardiomegalia, or simply “enlarged heart”. There were
villagers who had intermarried with other inhabitants of
their own village. This gave their children a propensity
to develop what was evidently hereditary cardiomegalia.
Those people who married to the individuals outside of
their own villages would have children exempt from the
disease. Although there was no evidence of interbreed-
ing, the findings did suggest that endogamous phenom-
ena with possible genetic reinforcement were at work.
Dr. Nikos Protonotarios finally obtained informed con-
sent after long discussions with the affected families on
Naxos and collected 12-lead ECGs of the cases he had.
The ECGs were brought to the Jean Rostand hospital,
Ivry-sur-Seine, France, for further analysis. It appeared
that the ECG signatures of the disease found on Naxos
were statistically comparable and seemed to be, if any-
thing, more pronounced than those from ARVD. In May
1994, GF visited Dr. Nikos Protonotarios and Dr. Ada-
lena Tsatsopoulou in Naxos. In the space of 3 days GF
saw 7 patients, all of whom GF gave thorough clinical
examinations. Each case was reviewed by ECG recorded
on a computerized Mac-PC Marquette electrocardio-
graph (American International Medical, California, USA)
and echocardiography (Toshiba Machine Co., Ltd.,
Shizuoka Prefecture, Japan). Each examination was ei-
ther preceded or followed by a handshake that gave tan-
gible proof of a thickening skin on the palm of the
patient’s hand. Individual cases were then discussed on
the basis of the available literature, the projection of
slides which showed histological images, and texts that
could help in understanding the concepts of ARVD.
After many interesting discussions and ideas followed, it
was convinced that there was a proof of a clearly defined
clinical entity in which the signs of palmoplantar kera-
tosis greatly facilitated its diagnosis. These signs were
closely associated with right ventricular anomalies on
both the structural and the electrocardiographic levels.
The term of “Naxos disease” was proposed. GF, Dr.
Nikos Protonotarios and colleagues finally presented an
abstract that included the name “Naxos disease” at the
AHA in 1994 in Dallas, Texas, USA [36].
“Naxos disease” then came into being as a genetically
determined family disease. The affliction presented with
palmoplantar keratosis, woolly hair, and the typical signs
of ARVD, but in a more severe form [13, 23, 27, 29, 30].
The severity corresponded to a more marked phenotypic
expression of a genetic mutation such as that governing
ARVD. Histological documentation was also in exist-
ence. Two patients with Naxos disease had been oper-
ated upon for VT in London. Pre-op biopsies on the
whole of the right ventricular wall clearly illustrated two
aspects that were typical of dysplasia. On the one hand,
pure dysplasia was evident. On the other, dysplasia asso-
ciated with elements that were suggestive of myocardial
phenomena involving the left ventricle was observed.
The latter phenomena were accompanied by changes in
cardiac function.
Dr. McKenna and his team pressed toward the identi-
fication of the gene responsible for Naxos disease. They
used the genetic identification method of links that
Fig. 8 A case of a 14 year old boy from Spain, who was admitted
into emergency room after being resuscitated from cardiac arrest,
secondary to malignant ventricular tachycardia that developed while
he was playing basketball. Four months later he was brought up
again to the emergency room after collapsing during mild exercise.
His MRI revealed more structural and functional anomalies of the
right ventricle, with more myocardial loss and more involvement at
layers of posterior and apical walls. The left ventricle was slightly
affected. Original materials from an open access article [58]
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allows the comparison of genomes of family members,
some of whom are affected and others are not. In 1996,
Dr. McKenna and his team further identified a critical
zone on chromosome 17 in position q21 [28]. In 1999,
McKenna indicated that researchers were on the verge
of identifying the gene responsible for Naxos disease at a
private meeting which was held in Berlin. In April 2000,
several days before setting off to Athens for a meeting of
the Greek Cardiological Society, GF received a phone
call from Dr. Adalena Tsatsopoulou and was told that
the Naxos disease gene had been clearly identified. It
involved the mutation of a protein, plakoglobin, con-
sidered to be responsible for both the cardiac anom-
aly and the palmoplantar keratosis. The work
identifying plakoglobin as the responsible protein for
Naxos disease proved to be a milestone in the study
of Naxos disease and ARVD [31]. After the Naxos
gene was identified, the pace at which knowledge ac-
cumulated speeded up considerably. A “knockout
mouse” which was produced in Berlin [37] showed
the gene surfacing through anomalies in the cutane-
ous tissue, but not through adipocytes in the right
ventricle. Research on the gene then carried out at an
infundibular idiopathic tachycardia level, showed the
positive results.
The protein plakoglobin is known to play a part in
cellular adhesion at the desmosomal level in cardiomyo-
cytes [12, 38]. It forms points of mechanical connection
between cells, and to which filaments of desmin are
attached. The armadillo protein plakoglobin is part of
the intermediate filaments. It is also homologous with
the keratin filaments found in cutaneous tissue. Identifi-
cation of the gene responsible for Naxos disease made it
possible to comprehend a connection between the heart
trouble linked to plakoglobin, the protein of the desmo-
some plaques to which the intermediate desmin fila-
ments attach themselves, and the rupture of mechanical
cutaneous desmosome links to which keratin attaches
itself. The rupture of these mechanical links produces a
reaction, in this case, a hyperplasia of the keratin layer
Fig. 9 Spontaneous sustained ventricular tachycardia originating from the right ventricular inferior wall, showing a left bundle branch block
configuration and superior axis. Original materials from an open access article [23]
Li et al. Orphanet Journal of Rare Diseases  (2018) 13:74 Page 7 of 11
similar to that to be seen in bullate skin complaints.
Disassociating these cells could induce a cellular trans-
differentiation phenomenon.
Sudden death from infundibular tachycardia: Genetic
explanation
A sixteen year old girl was at school when she jumped
up, held her hand to her chest and cried, “Oh ... my
heart!” Suddenly she went pale, lost consciousness and
collapses. The girl was slow to recover, the emergency
services were called. They attempt to resuscitate her but
it was too late, she had suffered irreversible brain dam-
age. Although brain-dead, the young girl survived for
more a week. During that time, infundibular ventricular
extrasystoles and inconsistent flickers of VT were re-
corded. The young girl suffered from right ventricular out-
flow tachycardia originating from the infundibular region.
The event in 1996 took place in the city of Tours (be-
tween France’s Cher and Loire rivers). Informed of it by
Prof. Pierre Cosnay, Hospital regional universities Cardi-
ologie, Tours, France, GF requested an autopsy wherein
the histological study would concentrate on the infun-
dibular region (Fig. 11). The study not only showed that
there were abnormal quantities of adipose tissue in the
infundibular region, but that there were also rows of car-
diomyocytes going right through this adipose tissue. Fi-
brosis and inflammation indicative of perimyocarditis, as
well as the presence of lymphocytes caught in a particu-
larly well-defined fibrosis, were also found. After review-
ing these data, we concluded that the tragedy was
caused by a localized form of ARVD with complications
arising from myocarditis, whose potential in the acute
deterioration of ARVD is known now [39–45]. Consider-
ing the absence of other reasonable evidences to be
discussed at the time of reviewing the documentation,
the indications were that these infundibular ventricular
extrasystoles and tachycardia were not as harmless as
generally supposed. Similar observations had been re-
corded in other cases. We know now that a considerable
Fig. 11 Sudden death in a 16-year-old girl. a and b, The infundibular
area and the adjacent zone with trabeculations show massive
adipocytes with surviving strands of cardiomyocytes, suggesting
a localized form of ARVD. c, Typical pattern of increased thickness of
the small coronary vessels. Red arrow, epicardium; Black arrow,
endocardium. Red square frame, increased thickness of the media
layer. (With permission from Fontaine GH) [10]
Fig. 10 Masson trichrome (a, magnification× 40) and Elastica–van
Gieson (b, magnification× 100) stained section from the right
ventricle of a patient with Naxos disease shows surviving strands of
cardiomyocytes bordered by or embedded in extensive fibro-fatty
tissue.(magnification× 40). (Courtesy of Dr. Nikos Protonotarios,
Naxos, Greece)
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percentage of idiopathic right ventricular outflow tachy-
cardia is localized forms of ARVD.
Several years later, and after the identification of the
Naxos disease gene, others who experienced infundibu-
lar tachycardia came into focus. The affected patients
from the same area as Naxos disease were tested for the
plakoglobin gene. All of the patients with Naxos disease
were found to be homozygous after genetic testings. The
infundibular tachycardia patients represented a heterozy-
gous expression of the illness. Given this information,
we formulated a “working hypothesis.” The patients who
had suffered from the infundibular tachycardia, in
general, were nothing other than the heterozygous ex-
pression of the illness. The aforementioned case of the
young girl had already highlighted the not entirely harm-
less nature of infundibular tachycardia. Patients who had
experienced these arrhythmias, upon evaluation by
means of angiography and magnetic resonance, had
shown structural anomalies in the infundibular region.
Carvajal syndrome
Carvajal syndrome, first described by Carvajal-Huerta in
Ecuador in 1998, is a variety of Naxos disease, [13, 16]
which has been reported in families from different re-
gions [16–18, 21, 46, 47]. It is usually inherited as an
autosomal recessive disorder due to defects in the des-
moplakin gene. Its clinical characteristics include woolly
hair and palmoplantar keratoderma and others as similar
to Naxos disease aforementioned. Carvajal syndrome at
the earlier stage during childhood presents with dilated
cardiomyopathy (Fig. 7) leading to a left dominant
phenotype of ARVD and most of these patients die dur-
ing adolescence [48]. Evidence for a wide genetic hetero-
geneity of ARVD, Naxos and Carvajal syndrome were
summarised in previous papers [13, 20, 21, 35, 49].
Recently emerging progress
Science has now identified at least 13 genes responsible
for typical cases of ARVD [50]. Therefore, the lessons
have been learned through the study of Naxos disease,
which first pointed at desmosomal abnormalities. These
genes could be tested as candidate genes in patients suf-
fering from infundibular ventricular tachycardia, which is
a rather frequent form in the spectrum of ARVC/Ds [51].
Over the past decades, a variety of biotechnologies are
emerging and have revolutionized the study of human
disorders [52–56]. These advances in biomedicine have
led to novel pathogenic insights of ARVD. One of the
most exciting crucial roles in revealing the pathogenesis
of ARVD is the recapitulation of “ARVD” using patient-
specific induced pluripotent stem cells [4, 21, 54]. Of
particular interest is the ARVD model published by V.
Chen’s group from San Diego, California, USA [54]. The
insights of pathological mechanisms of ARVD in this
study were consistent with our original hypothesis in
1977 that ARVD is a disorder of cardiac development,
[1, 54] renovate the notion that the presence of fatty-
fibrosis, not replacement of myocardium by fatty or fi-
brosis, are the pathological characteristics of ARVD. As
we said before, the establishment, evolution, pathogenic
findings, and potential therapies of ARVD finally run a
full circle, back to where the disease was identified [4].
All of these declarations are also applicable to the study
of Naxos disease.
Conclusion
Thanks to Naxos disease, a pure genetic disorder, a new
field of research was opened. Thanks to those with the
determination to discover Naxos disease, there is and
will be more clarity in understanding the mechanisms of
juvenile sudden death in the young who have an appar-
ently otherwise normal heart.
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